DDR1 Regulates Femoral Arterial Calcification in Lower‐Extremity Artery Disease Through NF ‐Kappa B Activation
Open Access
- 16 December 2025
- journal article
- Published by Wiley in Acta Physiologica
- Vol. 242 (1) , e70146
Abstract
Aim: Lower‐extremity arterial disease (LEAD) is a manifestation of atherosclerotic cardiovascular disease, affecting 230 million people worldwide with increasing prevalence. Medial arterial calcification (MAC) is common in LEAD patients and contributes to disease‐related mortality. However, therapeutic strategies targeting femoral MAC are lacking, and its underlying mechanisms remain unclear. This study aimed to identify molecular drivers of femoral MAC in LEAD. Methods & Results: Calcium deposits and pro‐calcifying markers were analyzed in human patient samples using von Kossa staining, immunofluorescence, and gene expression analysis. Femorals showed significantly more calcification and pro‐calcifying gene expression than carotids. Given MAC abundance in LEAD, we assessed medial calcification in Apoe−/− mice fed a WD for 4/21 weeks. Digital PCR revealed upregulation of Ddr1 and Bmp2 in femoral versus carotid arteries after 21 weeks of WD. DDR1 expression positively correlated with calcification in human femoral samples. In vitro experiments with mouse femoral vs. carotid vascular smooth muscle cells (VSMCs) confirmed a significantly higher prevalence of calcifying proteins (DDR1, BMP2, and RUNX2) in femoral VSMCs. Additionally, calcification analyses in murine and human VSMCs showed that DDR1 inhibition reduced, while DDR1 activation increased, calcium deposition. Transcriptomic analysis revealed elevated NF‐κB expression in human femoral arteries, matching data in femoral VSMCs. DDR1 stimulation activated NF‐κB, and its inhibition blocked DDR1‐induced calcification. Conclusion: This study identifies DDR1 as a key driver of calcification in LEAD, operating through NF‐κB activation and the expression of calcifying proteins. Targeting DDR1 may offer a novel therapeutic approach to prevent MAC in LEAD.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB1123‐A1)
- Deutsche Forschungsgemeinschaft (GO1804/9‐1)
- Deutsche Forschungsgemeinschaft (SFB/TRR219‐ID322900939‐(project‐C02‐to‐CG‐and‐M‐05‐to‐HN))
- Novartis Foundation (22B148)
- Jubiläumsstiftung von Swiss Life
- National Natural Science Foundation of China (82200065)
This publication has 28 references indexed in Scilit:
- Association between arterial stiffness and peripheral artery disease as measured by radial artery tonometryJournal of Vascular Surgery, 2017
- Prevalence of Nonatheromatous Lesions in Peripheral Arterial DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implicationsCatheterization and Cardiovascular Interventions, 2014
- Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expressionKidney International, 2012
- Carotid and femoral atherosclerotic plaques show different morphologyAtherosclerosis, 2011
- Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesisJournal of Cellular Biochemistry, 2010
- Discoidin Domain Receptor-1 Deficiency Attenuates Atherosclerotic Calcification and Smooth Muscle Cell-Mediated MineralizationThe American Journal of Pathology, 2009
- BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cellsAtherosclerosis, 2008
- Discoidin Domain Receptor 1 Receptor Tyrosine Kinase Induces Cyclooxygenase-2 and Promotes Chemoresistance through Nuclear Factor-κB Pathway ActivationCancer Research, 2006
- NF-κB Specifically Activates BMP-2 Gene Expression in Growth Plate Chondrocytes in Vivo and in a Chondrocyte Cell Line in VitroJournal of Biological Chemistry, 2003